市場調查報告書
商品編碼
1029295

全球青光眼藥物市場:行業趨勢、市場份額、市場規模、增長、機會、預測(2021-2026)

Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 143 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計 2020 年全球青光眼藥物市場將達到 68 億美元,並在 2021 年至 2026 年間以 6.3% 的複合年增長率增長。

青光眼在全球日益流行是推動市場增長的關鍵因素之一。除了糖尿病,青光眼在患有年齡相關性黃斑變性 (AMD)、白內障和乾眼症等眼病的患者中也很常見。與此同時,易患此類疾病的老年人口的增加對市場的增長產生了積極的影響。

公眾對健康的日益增長的認識以及對激光青光眼手術的興趣日益增長,也支持了市場的增長。此外,創新組合藥物的開發是另一個推動增長的因素。其他因素,如先進的青光眼診斷技術的出現和醫療基礎設施的發展,預計將進一步提振市場。

本報告調查了全球青光眼藥物市場、市場概況、表現、COVID-19 的影響、按藥物類別、適應症、最終用戶、地區、競爭形勢和主要公司進行的市場分析。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球青光眼治療藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章市場細分:按藥物類別

  • 前列腺素類似物
  • Beta 阻斷劑
  • ALPHA腎上腺素能激動劑
  • 碳酸酐□抑製劑
  • 聯合用藥
  • 其他

第 7 章市場細分:按適應症

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第 8 章市場細分:按最終用戶

  • 醫院
  • 眼科診所
  • 門診手術中心
  • 其他

第 9 章市場細分:按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東/非洲
    • 按國家/地區劃分的市場細分

第 10 章 SWOT 分析

第11章價值鏈分析

第十二章波特五力分析

第十三章價格分析

第14章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI S.p.A
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: SR1020F245_Report

The global glaucoma therapeutics market reached a value of US$ 6.8 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.3% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Glaucoma therapeutics refers to various treatment alternatives for primary open-angle (POA) and primary angle-closure (PAC) glaucoma. The disease is characterized by structural changes in the optic nerves that usually lead to visual loss and blindness. The treatment for glaucoma can be initiated through topical eye drops, which majorly consist of beta-blockers, prostaglandin analogs, cholinergic, carbonic anhydrase inhibitors and alpha-adrenergic agonists. These eye drops minimize the production of fluid in the eyes, thereby reducing the intraocular pressure (IOP). This can be followed by traditional or laser surgical procedures or a combination of both, which use products such as implantable extended-release devices, polymer-based contact lenses, drug-eluting punctal plugs, microneedle-injection devices and micro-dosing technologies.

The increasing prevalence of glaucoma across the globe represents one of the key factors driving the growth of the market. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye. In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth. Additionally, the development of innovative combination dugs is acting as another growth-inducing factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogs combined with two or more drugs to control the elevated levels of IOP. Other factors, including the advent of advanced glaucoma diagnostic techniques, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global glaucoma therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class, indication and end user.

Breakup by Drug Class:

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Breakup by Indication:

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

Breakup by End User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgery Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI S.p.A and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global glaucoma therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global glaucoma therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2020
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2020
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2020
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2021-2026
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million US$), 2021-2026
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players